Hostname: page-component-6766d58669-76mfw Total loading time: 0 Render date: 2026-05-18T09:13:51.744Z Has data issue: false hasContentIssue false

Dried chicory root improves bowel function, benefits intestinal microbial trophic chains and increases faecal and circulating short chain fatty acids in subjects at risk for type 2 diabetes

Published online by Cambridge University Press:  28 April 2022

Marie-Luise Puhlmann*
Affiliation:
Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands
Roosa Jokela
Affiliation:
Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
Katja Catharina Wilhelmina van Dongen
Affiliation:
Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands Division of Toxicology, Wageningen University & Research, Wageningen, The Netherlands
Thi Phuong Nam Bui
Affiliation:
Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands Caelus Health, Amsterdam, The Netherlands
Roland Willem Jan van Hangelbroek
Affiliation:
Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands Department of Data Science, Euretos BV, Utrecht, The Netherlands
Hauke Smidt
Affiliation:
Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands
Willem Meindert de Vos
Affiliation:
Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
Edith Johanna Maria Feskens
Affiliation:
Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands
*
Corresponding author. Email: marie-luise.puhlmann@wur.nl

Abstract

We investigated the impact of dried chicory root in a randomised, placebo-controlled trial with 55 subjects at risk for type 2 diabetes on bowel function, gut microbiota and its products, and glucose homeostasis. The treatment increased stool softness (+1.1 ± 0.3 units; p = 0.034) and frequency (+0.6 ± 0.2 defecations/day; p < 0.001), strongly modulated gut microbiota composition (7 % variation; p = 0.001), and dramatically increased relative levels (3-4-fold) of Anaerostipes and Bifidobacterium spp., in a dose-dependent, reversible manner. A synthetic community, including selected members of these genera and a Bacteroides strain, generated a butyrogenic trophic chain from the product. Faecal acetate, propionate and butyrate increased by 25.8 % (+13.0 ± 6.3 mmol/kg; p = 0.023) as did their fasting circulating levels by 15.7 % (+7.7 ± 3.9 μM; p = 0.057). In the treatment group the glycaemic coefficient of variation decreased from 21.3 ± 0.94 to 18.3 ± 0.84 % (p = 0.004), whereas fasting glucose and HOMA-ir decreased in subjects with low baseline Blautia levels (−0.3 ± 0.1 mmol/L fasting glucose; p = 0.0187; −0.14 ± 0.1 HOMA-ir; p = 0.045). Dried chicory root intake rapidly and reversibly affects bowel function, benefits butyrogenic trophic chains, and promotes glycaemic control.

Information

Type
Research Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Nutrition Society
Figure 0

Figure 1 Trial design of the randomised placebo-controlled parallel trial comparing dried chicory root intake with maltodextrin placebo. Asterisks indicate 3-day period (same weekdays) used for the calculation of continuous glucose monitoring metrics for baseline (T0), run-in (T1) and intervention period (T2). Created with BioRender.com.

Figure 1

Table 1. Baseline characteristics of all subjects included in the data analysis.

Figure 2

Figure 2 (A–D) Effect of dried chicory root consumption on overall gut microbiota composition [β-diversity, assessed by principal coordinates analysis (PCoA) with Bray–Curtis dissimilarity] at baseline (T0) after 2 weeks of 15 g/day treatment or iso-caloric placebo (T2), 3 weeks of 30 g/day treatment or iso-caloric placebo (T2) and after 2 weeks of wash-out (T3). No changes in α-diversity measures were observed, which reflects the within-person variation in microbiota composition by measuring the number (richness) of different bacterial taxa and their distribution (evenness) within a sample. (E) Gut microbiota composition at baseline (T0), 15 g/day treatment or iso-caloric placebo (T1), 30 g/day treatment or iso-caloric placebo (T2) and washout (T3). We observed a significant increase (↑) of Bifidobacterium spp. and Anaerostipes spp. at T1 and T2 in the treatment group and a significant decrease (↓) of Blautia spp. at T2. None of the taxa in the placebo group changed significantly between any of the timepoints. (F) Synthetic co- and tri-culture experiments. Metabolite production and consumption in a tri-culture containing Bacteroides xylanisolvens (B. xylanisolvens), Bifidobacterium animalis subsp. lactis BLC1 (B. animalis BLC1) and Anaerostipes rhamnosivorans 1y2T (A. rhamnosivorans) incubated with the treatment product consisting of dried chicory roots (5 g/L in YCFA) (Duncan et al., 2009). Mean values are shown with standard deviation after 7 days incubation at 37°C but 80 % of the conversion was already completed after 3 days of incubation (not shown). (G) Postulated microbial and metabolic interaction network involved in the colonic fermentation of the dried chicory roots (predominantly consisting of inulin, pectin and hemicellulose and cellulose). Proposed conversion by Bacteroides spp. is presented in green, by Bifidobacterium spp. in blue and by Anaerostipes spp. in red. The treatment product, dried chicory roots, consists of plant cells, which are envisaged to be degraded and liberate the intermediate products inulin, pectin and small sugars (like fructo-oligosaccharides) that are further converted into the end products (highlighted in orange) including propionate or butyrate via the intermediate products lactate and acetate.

Figure 3

Table 2. Levels and changes of faecal short-chain fatty acid levels at baseline (T0), after 2 weeks of 15 g/day treatment or 8 g/day iso-caloric placebo intake (T1), after 3 weeks of 30 g/day treatment or 16 g/day iso-caloric placebo intake (T2), and after 2 weeks of wash-out (T3).a

Figure 4

Table 3. Fasting circulating SCFA levels at baseline (T0), after 3 weeks of 30 g/day treatment or 16 g/day iso-caloric placebo intake (T2) and change (∆) over baseline.a

Figure 5

Figure 3 (A). Coefficient of variation (CV%) as a measure of glycaemic control assessed using continuous glucose measurement on three same consecutive weekdays during baseline (T0), the run-in period (T1) with 15 g/day treatment or 8 g/day iso-caloric placebo, and during the study period (T2) with 30 g/day treatment or 16 g/day isocaloric placebo (repeated-measures ANOVA with main effect of period p = 0.001, post-hoc tests with FDR-adjustment). Data is presented after sensitivity analysis excluding datasets with more than 20 % missing data and an extreme outlier (3 × IQR) for treatment (n = 22) and placebo group (n = 24). No difference between groups in baseline CV was observed before (p = 0.55) and after sensitivity analysis (p = 0.25). (B) Difference in relative abundance of Blautia spp. at baseline (T0) between HOMA-ir Responders (>10 % decrease, n = 8) and Non-Responders (>10 % increase) (C–E) Differences in changes in subjects with low (n = 14) or high (n = 14) baseline Blautia spp. relative abundance in the treatment group in (C) CV% as a measure of glycaemic control (low n = 13, high n = 14; repeated-measures ANOVA with main effect of period p < 0.001, post-hoc tests with FDR-adjustment), (D) fasting glucose levels and (E) HOMA-ir as glucose homeostasis markers (assessed using non-parametric testing). p < 0.05, ‡‡p < 0.01.

Supplementary material: PDF

Puhlmann et al. supplementary material

Puhlmann et al. supplementary material

Download Puhlmann et al. supplementary material(PDF)
PDF 1.2 MB